RxDoctor Payments Data

Manuel Guzman, MD

Cardiovascular Disease · San Juan, PRNPI 1891835427

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $194,908 of the $202,643 with a category attached, or 96.2%. Johnson & Johnson accounts for 99.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $60,298 and has fallen 99.4% since, to $350 in 2025. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$202,643in general payments, 2019–2025

Across 268 payments — averaging $756.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$201K
  • AstraZeneca$307
  • E.r. Squibb & Sons, L.L.C.$234
  • Amgen$166
  • PBG Puerto Rico LLC$150
  • Medtronic$134
  • plus $517 from 10 others

What the payments were for

  • Speaking & faculty fees$194,90896%
  • Travel & lodging$8590%
  • Food & beverage$6,8653%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)204$201,134
AstraZeneca18$307
E.r. Squibb & Sons, L.L.C.7$234
Amgen8$166
PBG Puerto Rico LLC8$150
Medtronic1$134
Abbott5$119
Boston Scientific2$107
Boehringer Ingelheim3$74
Merck3$60
Bayer Puerto Rico Inc.2$45
Pfizer Pharmaceuticals LLC2$32
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$25
AbbVie1$25
Biotronik Inc.1$24
Pfizer1$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$202,643 in reported general payments places this provider in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$32,486
Medicare patients
97
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban447$362,968
XareltoRivaroxaban225$263,761
EntrestoSacubitril/Valsartan116$114,556
JardianceEmpagliflozin72$70,584
FarxigaDapagliflozin Propanediol65$69,617
BrilintaTicagrelor64$36,715
Repatha SureclickEvolocumab55$34,599
Metoprolol Succinate1,322$29,375
Candesartan Cilexetil180$20,852
Losartan Potassium1,148$18,090
Atorvastatin Calcium1,154$16,606
JanuviaSitagliptin Phosphate11$16,265
SynthroidLevothyroxine Sodium203$15,408
Janumet XrSitagliptin Phos/Metformin Hcl20$14,833
Rosuvastatin Calcium570$9,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$6$362,968447 claims
Johnson & JohnsonXarelto$201,134$263,761225 claims
AstraZenecaFarxiga, Brilinta$307$106,332129 claims
Boehringer IngelheimJardiance$74$70,58472 claims
MerckJanuvia, Janumet Xr$60$31,09831 claims
AbbVieSynthroid$25$15,408203 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →